Epstein-Barr virus genes and cancer cells

Biomedicine and Pharmacotherapy

Volumn 51, Issue 6-7, 1997, Pages 258-267

  Farrell, P J ^a,b   Cludts, I ^a   Stuhler A ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Burkitt's lymphoma; Cancer therapy; Nasopharyngeal carcinoma

Indexed keywords

B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER CELL; CANCER THERAPY; CELL GROWTH; EPSTEIN BARR VIRUS; GENE EXPRESSION; HODGKIN DISEASE; HUMAN; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; REVIEW; T CELL LYMPHOMA;

EID: 0030748334     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(97)83541-X     Document Type: Article

References (82)

1. 1 Allday MJ, Sinclair A, Parker G, Crawford DH, Farrell PJ. Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53. EMBO J 1995;14:1382-91
2. 2 Bain M, Watson RJ, Farrell PJ, Allday MJ. Epstein-Barr virus Nuclear Antigen 3C is a Powerful Repressor of Transcription when Tethered to DNA. J Virol 1996;70: 2481-9
3. 3 Brooks L, Yao QY, Rickinson AB, Young LS. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP-2 transcripts. J Virol 1992;66:2689-97
4. 4 Brown NA, Liu CR, Wang YF, Garcia CR. B-cell lymphoproliferation and lymphomagenesis are associated with clonotypic intracellular terminal regions of the Epstein-Barr virus. J Virol 1988;62:962-9
5. 5 Chen HL, Lung MM, Sham JS, Choy DT, Griffin BE, Ng MH. Transcription of BamHI-A region of the EBV genome in NPC tissues and B cells. Virology 1992;191:193-201
6. 6 Clemens MJ. Functional Significance of the Epstein-Barr Virus-encoded Small RNAs. Epstein-Barr Virus Report 1994;1:107-11
7. 7 Cohen JI, Kieff E. An Epstein-Barr virus nuclear protein 2 domain essential for transformation is a direct transcriptional activator. J Virol 1991;65:5880-5
8. 8 Deacon EM, Pallesen G, Niedobitek G, Crocker J, Brooks L, Rickinson AB, Young LS. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med 1993;177:339-49
9. 9 Effert P, McCoy R, Abdel-Hamid M, Flynn K, Zhang Q, Busson P, Tursz T, Liu E, Raab-Traub N. Alterations of the p53 gene in nasopharyngeal carcinoma. J Virol 1992;66:3768-75
10. 10 Evans TJ, Brooks L, Farrell PJ. A strategy for specific targeting of therapeutic agents to tumour cells of virus-associated cancers. Gene Ther 1997;4:264-7
11. 11 Fahraeus R, Fu HL, Ernberg I, Finke J, Rowe M, Klein G, Falk K, Nilsson E, Yadav M, Busson P, et al. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 1988;42:329-38
12. 12 Farrell P. Epstein-Barr virus immortalizing genes. Trends Microbiol 1995;3:105-9
13. 13 Franken M, Estabrooks A, Cavacini L, Sherburn B, Wang F, Scadden D. Epstein-Barr virus-driven gene therapy for EBV related lymphoma. Nature Medicine 1996;2:1379-82
14. 14 Gahn TA, Sugden B. An EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein-Barr virus LMP gene. J Virol 1995;69:2633-6
15. 15 Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla-Favera R. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991;88:5413-7
16. 16 Gilligan KJ, Rajadurai P, Lin JC, Busson P, Abdel-Hamid M, Prasad U, Tursz T, Raab-Traub N. Expression of the Epstein-Barr virus BamHI A fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo. J Virol 1991;65:6252-9
17. 17 Gu W, Bhatia K, Magrath IT, Dang CV, Dalla-Favera R. Binding and Suppression of the Myc Transcriptional Activation Domain by p 107. Science 1994;264:251-4
18. 18 Gutierrez M, Judde J, Magrath I, Bhatia K. Switching viral latency to viral lysis: a novel therapeutic approach for Epstein-Barr virus-associated neoplasia. Cancer Res 1996;56:969-72
19. 19 Harabuchi Y, Yamanaka N, Kataura A, Imai S, Kinoshita T, Mizuno F, Osato T. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 1990;335:128-30
20. 20 Henkel T, Ling PD, Hayward SD, Peterson MG. Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. Science 1994;265: 92-5
21. 21 Herbst H, Dallenbach F, Hummel M, Niedobitek G, Pileri S, Muller-Lantzsch N, Stein H. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci USA 1991;88:4766-70
22. 22 Horner DS, Lewis M, Farrell PJ. Novel hypotheses for the roles of EBNA-1 and BHRF1 in EBV related cancers. Intervirology 1995;38:195-205
23. 23 Hsieh JJ, Henkel T, Salmon P, Robey E, Peterson MG, Hayward SD. Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2. Mol Cell Biol 1996;16:952-9
24. 24 Huang DP, Lo KW, Choi PH, Ng AY, Tsao SY, Yiu GK, Lee JC. Loss of heterozygosity on the short arm of chromosome 3 in nasopharyngeal carcinoma. Cancer Genet Cytogenet 1991;54:91-9
25. 25 Huang DP, Lo KW, van-Hasselt CA, Woo JK, Choi PH, Leung SF, Cheung ST, Cairns P, Sidransky D, Lee JC. A region of homozygous deletion on chromosome 9p21-22 in primary nasopharyngeal carcinoma. Cancer Res 1994;54:4003-6
26. 26 Huen DS, Henderson SA, Croom-Carter D, Rowe M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995;10:549-60
27. 27 Hui A, Lo K, Leung S, Choi P, Fong Y, Lee J, Huang D. Loss of heterozygosity on the long arm of chromosome 11 in nasopharyngeal carcinoma. Cancer Res 1996;56: 3225-9
28. 28 Imai S, Koizumi S, Sugiura M, Tokunaga M, Uemura Y, Yamamoto N, Tanaka S, Sato E, Osato T. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci USA 1994;91:9131-5
29. 29 Jacquemin M, Sinclair A, Farrell P. Gene expression in Burkitt's Lymphoma cells. In: Becker Y and Darai G, ed. Frontiers in Virology. Berlin: Springer-Verlag, 1994;283-97
30. 30 Jenkins P, Farrell P. Are particular Epstein-Barr virus strains linked to disease? Sem Cancer Biol 1996;7:209-15
31. 31 Johannsen E, Koh E, Mosialos G, Tong X, Kieff E, Grossman SR. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1. J Virol 1995;69:253-62
32. 32 Jones JF, Shurin S, Abramowsky C, Tubbs RR, Sciotto CG, Wahl R, Sands J, Gottman D, Katz BZ, Sklar J. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. N Engl J Med 1988;318:733-41
33. 33 Kaye K, Devergne O, Harada J, Izumi K, Yalamanchili R, Kieff E, Mosialos G. Tumor necrosis factor receptor associated factor 2 is a mediator of NF-κB activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci USA 1996;93:11085-90
34. 34 Kikuta H, Taguchi Y, Tomizawa K, Kojima K, Kawamura N, Ishizaka A, Sakiyama Y, Matsumoto S, Imai S, Kinoshita T, et al. Epstein-Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease. Nature 1988;333: 455-7
35. 35 Kitay M, Rowe D. Cell cycle stage-specific phosphorylation of the Epstein-Barr virus immortalization protein EBNA-LP. J Virol 1996;70:7885-93
36. 36 Klein G. In defence of the 'old' Burkitt lymphoma scenario. In: Klein G, ed. Advances in Viral Oncology. New York: Raven, 1987;207-211
37. 37 Kumar A, Haque J, Lacoste J, Hiscott J, Williams BR. Double-stranded RNA-dependent protein kinase activates transcription factor NF-kappa B by phosphorylating I kappa B. Proc Natl Acad Sci USA 1994;91:6288-92
38. 38 Laux G, Adam B, Strobl LJ, Moreau-Gachelin F. The Spi1/PU.1 and Spi-B ets family transcription factors and the recombination signal binding protein RBP-J kappa interact with an Epstein-Barr virus nuclear antigen 2 responsive cis-element. EMBO J 1994;13:5624-32
39. 39 Le-Roux A, Kerdiles B, Walls D, Declieu JF, Perricaudet M. The Epstein-Barr virus determined nuclear antigens EBNA-3A, -3B, and -3C repress EBNA-2-mediated transactivation of the viral terminal protein 1 gene promoter. Virology 1994;205:596-602
40. 40 Lenoir GM, Bornkamm GW. Burkitt's Lymphoma, A Human Cancer Model for the Study of the Multistep Development of Cancer: Proposal for a New Scenario. Advances in Viral Oncology 1987;7:173-206
41. 41 Li S, Chang Y, Liu S. Effect of a 10 amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein-Barr virus. Oncogene 1996;12:2129-35
42. 42 Lo K, Tsao S, Huang D, Lee J. Detailed deletion mapping on the short arm of chromosome 3 in nasopharyngeal carcinomas. Int J Oncol 1994;4:1359-64
43. 43 Lo KW, Huang DP, Lau KM. p16 gene alterations in nasopharyngeal carcinoma. Cancer Res 1995;55:2039-43
44. 44 Lupton S, Levine AJ. Mapping genetic elements of Epstein-Barr virus that facilitate extrachromosomal persistence of Epstein-Barr virus-derived plasmids in human cells. Mol Cell Biol 1985;5:2533-42
45. 45 Marshall D, Sample C. Epstein-Barr virus nuclear antigen 3C is a transcriptional regulator. J Virol 1995;69:3624-30
46. 46 Miller CL, Lee JH, Kieff E, Longnecker R. An integral membrane protein (LMP-2) blocks reactivation of EpsteinBarr virus from latency following surface immunoglobulin crosslinking. Proc Natl Acad Sci USA 1994;91:772-6
47. 47 Miller W, Mosialos G, Kieff E, Raab-Traub N. Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-κB activation. J Virol 1997;71:586-94
48. 48 Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995;80:389-99
49. 49 Neri A, Barriga F, Inghirami G, Knowles DM, Neequaye J, Magrath IT, Dalla-Favera R. Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma. Blood 1991;77:1092-5
50. 50 Nonkwelo C, Skinner J, Bell A, Rickinson A, Sample J. Transcription Start Sites Downstream of the Epstein-Barr Virus (EBV) Fp Promoter in Early-Passage Burkitt Lymphoma Cells Define a Fourth Promoter for Expression of the EBNA-1 Protein. J Virol 1996;70:623-7
51. 51 Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 1991;37:320-2
52. 52 Parker G, Crook T, Bain M, Sara E, Farrell P, Allday M. Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene 1996;13: 2541-9
53. 53 Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 1995;333:693-8
54. 54 Poppema S, van-Imhoff G, Torensma R, Smit J. Lymphadenopathy morphologically consistent with Hodgkin's disease associated with Epstein-Barr virus infection. Am J Clin Pathol 1985;84:385-90
55. 55 Qu L, Rowe DT. Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J Virol 1992;66:3715-24
56. 56 Raab-Traub N. Epstein-Barr virus and nasopharyngeal carcinoma. Seminars in Cancer Biology 1993;3:297-307
57. 57 Rawlins DR, Milman G, Hayward SD, Hayward GS. Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell 1985;42:859-68
58. 58 Rickinson AB, Kieff E. Epstein-Barr Virus. In: Fields BN, Knipe PM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott-Raven, 1996;2397-446
59. 59 Robertson E, Kieff E. Genetic analysis of Epsten-Barr virus in B lymphocytes. Epstein-Barr Virus Report 1995;2:73-80
60. 60 Robertson ES, Lin J, Kieff E. The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa). J Virol 1996;70:3068-74
61. 61 Robertson ES, Tomkinson B, Kieff E. An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitro. J Virol 1994;68:1449-58
62. 62 Robertson KD, Hayward SD, Ling PD, Samid D, Ambinder RF. Transcriptional activation of the Epstein-Barr virus latency C promoter after 5-azacytidine treatment: evidence that demethylation at a single CpG site is crucial. Mol Cell Biol 1995;15:6150-9
63. 63 Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, Rupani H, Rickinson AB. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 1987;6:2743-51
64. 64 Schaefer BC, Strominger JL, Speck SH. Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. Proc Natl Acad Sci USA. 1995;92: 10565-69
65. 65 Shiramizu B, Barriga F, Neequaye J, Jafri A, Dalla-Favera R, Neri A, Guttierez M, Levine P, Magrath I. Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: relevance to geography and Epstein-Barr virus association. Blood 1991;77:1516-26
66. 66 Sinclair AJ, Farrell PJ. Epstein-Barr virus transcription factors. Cell Growth Differ 1992;3:557-63
67. 67 Sinclair AJ, Palmero I, Peters G, Parrel PJ. EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J 1994;13:3321-8
68. 68 Smith PR, Gao Y, Karran L, Jones MD, Snudden D, Griffin BE. Complex nature of the major viral polyadenylated transcripts in Epstein-Barr virus-associated tumors. J Virol 1993;67:3217-25
69. 69 Spruck C, Tsai YC, Huang DP, Yang AS, Rideout W, Gonzalez-Zulueta M, Choi P, Lo KW, Yu MC, Jones PA. Absence of p53 gene mutations in primary nasopharyngeal carcinomas. Cancer Res 1992;52:4787-90
70. 70 Sugden B, Warren N. A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection. J Virol 1989;63:2644-9
71. 71 Sun Y, Hildesheim A, Lanier AE, Cao Y, Yao KT, Raab-Traub N, Yang CS. No point mutation but decreased expression of the p16/MTS1 tumor suppressor gene in nasopharyngeal carcinomas. Oncogene 1995;10:785-8
72. 72 Tomita Y, Ohsawa M, Kanno H, Hashimoto M, Ohnishi A, Nakanishi H, Aozasa K. Epstein-Barr virus in Hodgkin's Disease Patients in Japan. Cancer 1996;77:186-92
73. 73 Vousden KH, Farrell PJ. Viruses and human cancer. Br Med Bull 1994;50:560-81
74. 74 Waltzer L, Perricaudet M, Sergeant A, Manet E. Epstein-Barr virus EBNA3A and EBNA3C proteins both repress RBP-J kappa-EBNA2-activated transcription by inhibiting the binding of RBP-J kappa to DNA. J Virol 1996;70: 5909-15
75. 75 Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985;43:831-40
76. 76 Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, Murray R, Rickinson A, Kieff E. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 1990;64:2309-18
77. 77 Wilson JB, Bell JL, Levine AJ. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J 1996;15:3117-26
78. 78 Wu TC, Mann RB, Charache P, Hayward SD, Staal S, Lambe BC, Ambinder RF. Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int J Cancer 1990;46:801-4
79. 79 Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985;313:812-5
80. 80 Young LS, Dawson CW, Clark D, Rupani H, Busson P, Tursz T, Johnson A, Rickinson AB. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 1988;69:1051-65
81. 81 Zhao B, Marshall DR, Sample CE. A conserved domain of the Epstein-Barr virus nuclear antigens 3A and 3C binds to a discrete domain of Jkappa. J Virol 1996;70:4228-36
82. 82 Zimber-Strobl U, Kempkes B, Marschall G, Zeidler R, Van Kooten C, Banchereau J, Bornkamm G, Hammerschmidt W. Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. EMBO J 1996;15:7070-8